Literature DB >> 25287768

Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar.

Nevin C Baker1, Michael J Lipinski1, Thibault Lhermusier1, Ron Waksman2.   

Abstract

Keywords:  acute coronary syndrome; platelet aggregation inhibitors; thrombolytic therapy

Mesh：

Substances：

Year:  2014        PMID： 25287768     DOI： 10.1161/CIRCULATIONAHA.114.011471

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  12 in total

Review 1.  Antithrombotic therapy in 2014: Making headway in anticoagulant and antiplatelet therapy.

Authors:  Jawed Fareed
Journal:  Nat Rev Cardiol       Date:  2015-01-13       Impact factor: 32.419

Review 2.  Protease-activated receptors in hemostasis.

Authors:  Marvin T Nieman
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

3.  PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy.

Authors:  Xu Han; Marvin T Nieman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-02       Impact factor: 8.311

4.  Race differences in platelet reactivity: is protease activated receptor 4 a predictor of response to therapy?

Authors:  Michele M Mumaw; Marvin T Nieman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-12       Impact factor: 8.311

Review 5.  Protease-activated receptor-1 (PAR-1): a promising molecular target for cancer.

Authors:  Xuan Liu; Jiahui Yu; Shangjin Song; Xiaoqiang Yue; Qi Li
Journal:  Oncotarget       Date:  2017-09-18

6.  Purification and Characterization of a Novel Antiplatelet Peptide from Deinagkistrodon acutus Venom.

Authors:  Yi Kong; Qing Sun; Qi Zhao; Yaqiong Zhang
Journal:  Toxins (Basel)       Date:  2018-08-16       Impact factor: 4.546

7.  Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial.

Authors:  Leo Ungar; Robert M Clare; Fatima Rodriguez; Bradley J Kolls; Paul W Armstrong; Philip Aylward; Claes Held; David J Moliterno; John Strony; Frans Van de Werf; Lars Wallentin; Harvey D White; Pierluigi Tricoci; Robert A Harrington; Kenneth W Mahaffey; Chiara Melloni
Journal:  J Am Heart Assoc       Date:  2018-12-18       Impact factor: 5.501

Review 8.  Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

Authors:  Behnood Bikdeli; Mahesh V Madhavan; Aakriti Gupta; David Jimenez; John R Burton; Caroline Der Nigoghossian; Taylor Chuich; Shayan Nabavi Nouri; Isaac Dreyfus; Elissa Driggin; Sanjum Sethi; Kartik Sehgal; Saurav Chatterjee; Walter Ageno; Mohammad Madjid; Yutao Guo; Liang V Tang; Yu Hu; Laurent Bertoletti; Jay Giri; Mary Cushman; Isabelle Quéré; Evangelos P Dimakakos; C Michael Gibson; Giuseppe Lippi; Emmanuel J Favaloro; Jawed Fareed; Alfonso J Tafur; Dominic P Francese; Jaya Batra; Anna Falanga; Kevin J Clerkin; Nir Uriel; Ajay Kirtane; Claire McLintock; Beverley J Hunt; Alex C Spyropoulos; Geoffrey D Barnes; John W Eikelboom; Ido Weinberg; Sam Schulman; Marc Carrier; Gregory Piazza; Joshua A Beckman; Martin B Leon; Gregg W Stone; Stephan Rosenkranz; Samuel Z Goldhaber; Sahil A Parikh; Manuel Monreal; Harlan M Krumholz; Stavros V Konstantinides; Jeffrey I Weitz; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2020-05-30       Impact factor: 5.249

Review 9.  Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma.

Authors:  Aditi Kothari; Matthew J Flick
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 6.208

Review 10.  Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.

Authors:  Judy Wm Cheng
Journal:  Vasc Health Risk Manag       Date:  2016-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.